Basecamp Valued at 800M in Series C
AI drug developer Basecamp Research has raised 140 million dollars in a Series C funding round, pushing its valuation to 800 million dollars. The company plans to use the capital to train new biological foundation models and advance its pipeline toward clinical development.
Xurve View
Insights:
Xurve View
AI-based drug developer Basecamp raised $140 million in a Series C funding round on Wednesday morning, reaching an $800 million valuation. The oversubscribed financing was led by S32 alongside backing from NVIDIA CORP and the NATO Innovation Fund. Basecamp will use the capital to advance its computational drug pipeline toward clinical testing.
